A new standard of care or just another option for patients with relapsed ovarian cancer?
Mené au Etats-Unis, au Japon, et en Corée du sud sur 674 patientes atteintes d'un cancer épithélial de l'ovaire, d'un cancer primitif du péritoine ou des trompes de Fallope sensible aux sels de platine et récidivant, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout du bévacizumab à une chimiothérapie combinant paclitaxel et carboplatine
The standard of care in patients with late relapse of ovarian cancer is platinum-based re-induction chemotherapy. So far, multiple platinum-based options have shown activity within randomised phase 3 trials. Still open are the questions of further chemotherapy options in the combination of bevacizumab and the role of surgery. In The Lancet Oncology, Robert Coleman and colleagues report the results of the GOG-0213 study,1 which has investigated these two questions: the role of surgery and the effect of the addition of bevacizumab to chemotherapy in women with recurrent, platinum-sensitive ovarian cancer
The Lancet Oncology , commentaire, 2016